1832 Asset Management
MIRM icon

1832 Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

1832 Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,800
Closed -$5.56M – 739
2025
Q3 		$5.56M Buy
+75,800
New +$4.82M ﹤0.01% 370

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

1832 Asset Management's MIRM Position: Q4 2025 in Review

1832 Asset Management sold out of Mirum Pharmaceuticals (MIRM) in Q4 2025, closing a stake of 75,800 shares — an estimated $5.56M sold.

1832 Asset Management first reported a position in MIRM in Q3 2025 and held it in 1 quarter. The position peaked at $5.56M in Q3 2025. 282 funds tracked by Wall St. Rank hold MIRM as of Q4 2025.

  • 1832 Asset Management reported no remaining Mirum Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • 1832 Asset Management sold 75,800 Mirum Pharmaceuticals shares in Q4 2025, an estimated $5.56M.
  • 1832 Asset Management first reported a position in Mirum Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • 1832 Asset Management's Mirum Pharmaceuticals position peaked at $5.56M in Q3 2025.
  • 282 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2025.

Based on 1832 Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.